Spark Therapeutics Inc. (NASDAQ:ONCE)‘s stock had its “buy” rating reiterated by analysts at JPMorgan Chase & Co. in a report issued on Monday.
Several other brokerages have also recently issued reports on ONCE. Zacks Investment Research cut Spark Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 16th. Cantor Fitzgerald restated a “buy” rating and issued a $94.00 price objective on shares of Spark Therapeutics in a research note on Thursday, August 11th. Wedbush restated an “underperform” rating and issued a $29.00 price objective (up from $28.00) on shares of Spark Therapeutics in a research note on Wednesday, August 10th. Jefferies Group restated a “hold” rating on shares of Spark Therapeutics in a research note on Friday, August 5th. Finally, Stifel Nicolaus assumed coverage on Spark Therapeutics in a research note on Friday, September 2nd. They issued a “buy” rating and a $73.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $60.75.
Spark Therapeutics (NASDAQ:ONCE) traded up 1.65% on Monday, reaching $56.54. The company had a trading volume of 184,178 shares. The stock’s 50 day moving average is $53.56 and its 200-day moving average is $54.23. Spark Therapeutics has a 1-year low of $21.20 and a 1-year high of $65.99. The stock’s market capitalization is $1.74 billion.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by $0.06. Spark Therapeutics had a negative return on equity of 28.28% and a negative net margin of 441.05%. The firm earned $1.30 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same quarter in the previous year, the business earned ($0.70) earnings per share. The company’s revenue for the quarter was up .0% compared to the same quarter last year. On average, equities analysts predict that Spark Therapeutics will post ($4.17) EPS for the current fiscal year.
In other news, insider Barge Joseph La sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $60.14, for a total value of $180,420.00. Following the transaction, the insider now owns 8,325 shares in the company, valued at $500,665.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jeffrey D. Marrazzo sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, October 17th. The shares were sold at an average price of $54.66, for a total value of $273,300.00. Following the completion of the transaction, the chief executive officer now owns 235,000 shares in the company, valued at approximately $12,845,100. The disclosure for this sale can be found here. 9.60% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its position in Spark Therapeutics by 10.6% in the second quarter. FMR LLC now owns 4,499,326 shares of the company’s stock valued at $230,051,000 after buying an additional 432,868 shares during the period. Price T Rowe Associates Inc. MD increased its position in Spark Therapeutics by 9.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 2,906,496 shares of the company’s stock valued at $174,564,000 after buying an additional 248,309 shares during the period. Vanguard Group Inc. increased its position in Spark Therapeutics by 28.9% in the second quarter. Vanguard Group Inc. now owns 1,512,600 shares of the company’s stock valued at $77,340,000 after buying an additional 338,720 shares during the period. JPMorgan Chase & Co. increased its position in Spark Therapeutics by 98.7% in the second quarter. JPMorgan Chase & Co. now owns 1,349,580 shares of the company’s stock valued at $69,003,000 after buying an additional 670,360 shares during the period. Finally, Baker BROS. Advisors LP purchased a new position in Spark Therapeutics during the third quarter valued at $79,180,000. Institutional investors and hedge funds own 81.69% of the company’s stock.
Spark Therapeutics Company Profile